EUCTR2007-007580-24-NL进行中（未招募）不适用
A double blind, randomized, 3-arm placebo controlled study to investigate the subjective and physiological efficacy and safety of Lybrido and Lybridos in the domestic setting in healthy female subjects with Female Sexual Dysfunction - Lybrido(s)@Home
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •1 Subjects must have a heterosexual orientation.
- •2 Subjects must be between 21 and 65 years of age.
- •3 Subjects must have experienced low sexual arousal and / or low sexual desire for at least six months prior to study entry according to DSM IV criteria. The diagnosis will be made by an experienced psychologist/sexologist.
- •4 Subjects must have signed the Informed Consent Form.
- •5 Inclusion will be following the selection criteria including, but not limited to, a physical examination, gynecological examination, medical history, vital signs, pregnancy test and ECG, and by the scoring on the Stroop task during familiarization trial.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years)
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1 Use of oral contraception containing anti-androgens (Like Diane 35 or Minerva);
- •2 Use of oral contraception containing 50 µg estrogen or more;
- •3 Pregnancy, or intention to become pregnant during this study (Note: a serum or urine pregnancy test will be performed in all women prior to the administration of study medications);
- •4 A pelvic inflammatory disease or an untreated vaginal infection at screening;
- •5 Lactating or subjects who have given birth in the previous 6 months;
- •6 Previous prolapse and incontinence surgery affecting the vaginal wall;
- •7 Women with other unexplained gynecological complaints, such as abnormal uterine bleeding patterns;
- •8 History of endocrinological treatment or current endocrinological treatment (with the exception of the use oral contraceptives and of fertility-promoting treatment);
- •9 History of neurological treatment or current neurological treatment;
- •10 History of serious psychiatric treatment or current psychiatric treatment;
- •11 Any underlying cardiovascular condition including unstable angina pectoris, that would preclude sexual activity;
- •12 History of myocardial infarction, stroke or life-threatening arrhythmia within the prior 6 months;
- •13 Uncontrolled atrial fibrillation/flutter at screening (ventricular response rate > 100 bpm), or other significant abnormality observed on ECG;
- •14 Systolic blood pressure > 140 mmHg and/or diastolic blood pressure > 90 mmHg. For subjects with age > 60 years and without diabetic mellitus, familiar hypercholesterolemia or cardiovascular disease: Systolic blood pressure > 160 mmHg and/or diastolic blood pressure > 90 mmHg (According to the CBO-guideline hypertension (CBO.2000a)).
- •15 Subjects who are taking strong CYP3A4-inhibitors: ritonavir (HIV-proteaseremmer), ketoconazol en itraconazol
- •16 Subjects who are taking less strong CYP3A4-inhibitors: claritromycine, erytromycine en saquinavir
- •17 Subjects who are taking CYP3A4-inducers: carbamazepine, fenytoïne, fenobarbital, st Johns Wort, rifampicine
- •18 Severe chronic or acute liver disease, history of moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment;
- •19 Use of medicinal herb as Ginkgo Biloba, St John's wort and nutrition containing grapefruit; avoid valerian, gotu kola, kava kava (may increase CNS depression)
- •20 Subjects who are taking nitrates or nitric oxide donors;
- •21 Subjects who are taking MAO inhibitors (includes classic MAO inhibitors and linezolid), Calcium channel blockers (e.g. Diltiazem and verapamil), Nefazodone, SSRIs, TCAs;
- •22 A substance abuse disorder that in the opinion of the investigator is likely to affect the subject's ability to complete the study or precludes the subject’s participation in the study; mild or moderately alcohol drinking behavior is allowed, only 12 hours before the experimental days is alcohol drinking not allowed. Three weeks before the start of the experimental day is the taking of any recreational drug not allowed. Smoking is allowed.
- •23 Use of any treatment for FSD within the 7 days before visit 1 or during the study, including oral medications or constrictive devices;
- •24 Subjects who are illiterate, unwilling or unable to understand and complete the questionnaires;
- •25 Any other clinically significant abnormality or condition which in the opinion of investigator would interfere with the participant’s ability to provide informed consent, comply with study instructions, possibly confound interpretation of study results, or endanger the participant if
研究者
相似试验
进行中（未招募）
1 期
Supplementation of VigantOL® Oil versus Placebo as Add-on in Patientswith Relapsing-Remitting MS receiving Rebif® treatment.Relapsing-Remitting Multiple SclerosisMedDRA version: 14.0Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2010-020328-23-PTMerck Serono SA - Geneva, an affiliate of Merck KGaA,358
进行中（未招募）
不适用
A three-arm, randomized, double-blind, placebo controlled, multicenter, phase II study to evaluate the efficacy of Vigantol® oil as add-on therapy in subjects with Relapsing-Remitting Multiple Sclerosis receiving treatment with Rebif®SOLARSupplementation of VigantOL® Oil versus Placebo as Add-on in Patients with Relapsing-Remitting MS receiving Rebif® treatment. - SOLARRelapsing-Remitting Multiple SclerosisMedDRA version: 12.1Level: LLTClassification code 10063399Term: Relapsing-remitting multiple sclerosisEUCTR2010-020328-23-NLMerck Serono The Netherlands - a division of Merck B.V.358
进行中（未招募）
不适用
Supplementation of VigantOL® Oil versus Placebo as Add-on in Patients with Relapsing-Remitting MS receiving Rebif® treatment.Relapsing-Remitting Multiple SclerosisMedDRA version: 14.1Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2010-020328-23-EEMerck Serono230
进行中（未招募）
不适用
Supplementation of VigantOL® Oil versus Placebo as Add-on in Patientswith Relapsing-Remitting MS receiving Rebif® treatment.EUCTR2010-020328-23-FIMerck Serono230
进行中（未招募）
不适用
Supplementation of VigantOL® Oil versus Placebo as Add-on in Patientswith Relapsing-Remitting MS receiving Rebif® treatment.Relapsing-Remitting Multiple SclerosisMedDRA version: 14.1Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2010-020328-23-LTMerck Serono230